School of Health and Exercise Sciences, University of British Columbia Okanagan, Kelowna, BC, Canada.
Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, UK.
J Physiol. 2018 Apr 15;596(8):1385-1395. doi: 10.1113/JP275709. Epub 2018 Mar 2.
The recent development of exogenous ketone supplements allows direct testing of the metabolic effects of elevated blood ketones without the confounding influence of widespread changes experienced with ketogenic diets or prolonged fasting. In the present study, we determined the effect of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester on the glycaemic response and insulin sensitivity index during a 2 h oral glucose tolerance test (OGTT) in humans. The results obtained show that consuming a ketone monoester supplement 30 min prior to an OGTT reduced the glycaemic response and markers of insulin sensitivity without affecting insulin secretion. The findings of the present study provides evidence that ketone supplements could have therapeutic potential for future application as a glucose-lowering nutritional supplement.
The main objectives of the present study were: (i) to determine whether acute ingestion of ketone monoester (K ); (R)-3-hydroxybutyl (R)-3-hydroxybutyrate impacts plasma glucose levels during a standardized oral glucose tolerance test (OGTT) and (ii) to compare changes in insulin concentrations and estimates of insulin sensitivity after acute K supplementation. Twenty healthy participants (n = 10 males/females) aged between 18 and 35 years took part in a randomized cross-over study. After an overnight fast, participants consumed a K supplement (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.45 ml kg body weight) or placebo (water) 30 min before completing a 75 g OGTT. Blood samples were collected every 15-30 min over 2.5 h. The participants and study personnel performing the laboratory analyses were blinded to the study condition. K acutely raised blood d-beta-hydroxybutyrate (β-OHB) to 3.2 ± 0.6 mm within 30 min with levels remaining elevated throughout the entire OGTT. Compared to placebo, K significantly decreased the glucose area under the curve (AUC; -17%, P = 0.001), non-esterified fatty acid AUC (-44%, P < 0.001) and C-peptide incremental AUC (P = 0.005), at the same time as improving oral glucose insulin sensitivity index by ∼11% (P = 0.001). In conclusion, a K supplement that acutely increased β-OHB levels up to ∼3 mm attenuated the glycaemic response to an OGTT in healthy humans. The reduction in glycaemic response did not appear to be driven by an increase in insulin secretion, although it was accompanied by improved markers of insulin sensitivity. These results suggest that ketone monoester supplements could have therapeutic potential in the management and prevention of metabolic diseases.
外源性酮补充剂的最新发展允许在不受到广泛的生酮饮食或长时间禁食所带来的影响的情况下,直接测试血液酮升高的代谢效应。在本研究中,我们确定了(R)-3-羟基丁基(R)-3-羟基丁酸单酯对人体 2 小时口服葡萄糖耐量试验(OGTT)期间血糖反应和胰岛素敏感指数的影响。研究结果表明,在 OGTT 前 30 分钟摄入酮单酯补充剂可降低血糖反应和胰岛素敏感性标志物,而不影响胰岛素分泌。本研究的结果提供了证据,表明酮补充剂可能具有治疗潜力,可作为未来降低血糖的营养补充剂应用。
本研究的主要目的是:(i)确定急性摄入酮单酯(K);(R)-3-羟基丁基(R)-3-羟基丁酸是否会影响标准化口服葡萄糖耐量试验(OGTT)期间的血浆葡萄糖水平,以及(ii)比较急性 K 补充后胰岛素浓度和胰岛素敏感性估计值的变化。20 名年龄在 18 至 35 岁之间的健康参与者(n=10 名男性/女性)参加了一项随机交叉研究。禁食过夜后,参与者在完成 75g OGTT 前 30 分钟内服用 K 补充剂(ΔG®;TΔS Ltd,英国牛津,英国;0.45ml/kg 体重)或安慰剂(水)。在 2.5 小时内每隔 15-30 分钟采集一次血样。进行实验室分析的参与者和研究人员对研究条件进行了盲法处理。K 在 30 分钟内将血液 D-β-羟基丁酸(β-OHB)急性升高至 3.2±0.6mm,整个 OGTT 期间β-OHB 水平持续升高。与安慰剂相比,K 显著降低了葡萄糖曲线下面积(AUC;-17%,P=0.001)、非酯化脂肪酸 AUC(-44%,P<0.001)和 C 肽增量 AUC(P=0.005),同时改善了口服葡萄糖胰岛素敏感性指数约 11%(P=0.001)。总之,急性升高β-OHB 水平至约 3mm 的 K 补充剂可减轻健康人群对 OGTT 的血糖反应。血糖反应的降低似乎不是由胰岛素分泌增加引起的,尽管它伴随着胰岛素敏感性标志物的改善。这些结果表明,酮单酯补充剂可能具有治疗潜力,可用于代谢疾病的管理和预防。